SIBN (53) BBNX (39) SGP (43) IRMD (59) ⌘ Pro Terminal →

Integra LifeSciences Holdings Corporation (IART) — RQD Stock Rating Cockpit

$12.75 -0.62% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $12.71

Integra LifeSciences Holdings Corporation (IART) carries a Roarable Rating of E (Strong Sell) with 20/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (20/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $998.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IART Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IART stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Integra LifeSciences Holdings Corporation (NASDAQ: IART) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 20/100 at a spot price of $12.75 (-0.62% 1D, market cap $998.2M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 3/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IART ranks #987 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IART compare to SIBN and BBNX in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), IART carries a Roarable E (20/100 RQD), trailing P/E of N/A, gross margin of 50.9%, and ROIC of -35.0%. By comparison, SIBN (SI-BONE Inc.) holds a D+ grade (53/100 RQD, P/E N/A, ROIC -10.3%, cap $1.00B) and BBNX (Beta Bionics Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -22.1%, cap $955.8M). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IART?

▼

Per IART's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000917520), Integra LifeSciences Holdings Corporation generated $1.64B in revenue (+1.5% YoY), -$516.8M in net income, and -$31.1M in free cash flow against $3.60B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $12.71 (-0.30%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (20/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-17.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IART)Realized 20D OHLCV Swing Band: ±11%

Deterministic 5-Pillar Attribution (20/100 Composite)

🔍 WHY IART SCORES 20/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+6/20 pts (30% of score)

Altman Z-Score 0.64 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Whale & Options Positioning+5/20 pts (25% of score)

20D Institutional Volume Accumulation (±11% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$13.98-3.8% Next Q

Q2 (-2Q)

Grade E$13.45-10% Next Q

Q3 (-1Q)

Grade E$12.10+5.4% Next Q

Current

Grade E$12.75-11.8% Hist 90D α

Trajectory: E (28) → E (20)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IART Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IART currently carries a cautious 20/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($14.76) and Max Pain ($13.39) forces dealer call-delta covering toward $21.51.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IART• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “IART Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 20%NO 80%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

43.730 Oversold · 70 Hot

ALTMAN-Z SHIELDDISTRESS RISK (<1.8)

0.64>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

4 / 99-Pt Accounting

52-WEEK LASER RANGE34% OF RANGE

L: $9$12.75H: $20

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 3 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 8 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 9 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on IART

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (15)

-35.0% ROIC with 50.9% gross margin and -3.11% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (30)

Altman-Z 0.64 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (18)

8/40 institutional & smart-money positioning score with 3/20 macro alignment.

Bull Case: Why Buyers Like IART

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IART)

✓Walkthrough of IART's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IART // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +19.72%▼ DESCENDING CHANNEL

2026-11-02O $12.24H $12.83L $12.24C $12.75VOL 1.19M

RES: $15.36SUP: $10.97SMA50: $14.76SMA200: $14.07

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IART Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IART Butterfly Map → + Track IART →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +1.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IART today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IART. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IART today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IART)

Health Care Rank #987 of 1016 ⚔️ SIBN vs IART Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IART vs. SIBN, BBNX, SGP, IRMD)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Integra LifeSciences Holdings Corporation (IART) ranks #987 by composite RQD confidence (20/100, grade E) and #361 by equity capitalization ($998.2M). Within this direct 5-issuer industry benchmark cohort, IRMD leads on earnings valuation at 48.8x trailing P/E, while IRMD leads on capital efficiency and profitability with 37.7% ROIC and 76.7% gross margin. IRMD currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with IART at 20/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IART ACTIVE Integra LifeSciences Holdings Corporation	E	20/100	—	50.9%	-35.0%	-0.62%	$998.2M	Benchmark Subject
SIBN SI-BONE Inc.	D+	53/100	—	79.6%	-10.3%	-5.27%	$1.00B	/sibn-vs-iart →
BBNX Beta Bionics Inc.	D-	39/100	—	55.4%	-22.1%	-4.72%	$955.8M	/bbnx-vs-iart →
SGP SpyGlass Pharma Inc.	D-	43/100	—	—	-35.0%	-0.83%	$1.09B	/sgp-vs-iart →
IRMD iRadimed Corporation	C-	59/100	48.8x	76.7%	37.7%	-10.57%	$1.10B	/irmd-vs-iart →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000917520

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Integra LifeSciences Holdings Corporation (IART) reported GAAP revenue of $1.64B (+1.5% vs. FY2024 revenue of $1.61B , and +6.1% cumulative change since FY2023) , GAAP net income of -$516.8M, operating cash flow of $50.4M, and free cash flow of -$31.1M (-224.4% YoY). On the balance sheet, IART closed FY2025 with $3.60B in total assets against $0 in total debt (Altman Z-Score: 0.64, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.64B	-$516.8M	$50.4M	-$31.1M	$3.60B	—
FY2024 (FY)	2024-12-31	$1.61B	-$6.9M	$129.4M	$25.0M	$4.04B	—
FY2023 (FY)	2023-12-31	$1.54B	$67.7M	$140.0M	$140.0M	—	—

3. IART Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IART stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does IART compare to SIBN and BBNX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for IART?

Where is IART trading relative to its 50-day, 200-day, and 52-week technical levels?

IART last traded at $12.75 (-0.62% on volume of 1,038,790 shares), positioning the stock -13.62% below its 50-day simple moving average ($14.76) and -9.38% below its 200-day simple moving average ($14.07). Across its 52-week range of $8.70 to $20.49, IART sits at the 34.4% percentile with a 14-day RSI of 43.7 (NEUTRAL RANGE) and an implied next-earnings move of ±11.0% ($11.35 to $14.15).

IART Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell IART stock right now?

Integra LifeSciences Holdings Corporation (IART) currently earns a Roarable Rating of E (Strong Sell — SELL) with 20/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is IART's 12-month price target and RQD AI Jury consensus?

IART's 12-month base price target is $10.57 (range $8.24 to $21.51), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: IART RQD Cockpit IART 12M Forecast IART Earnings & Move IART Dividends & DRIP IART Insiders & 13F IART Whale Options IART Profit Sankey IART News & Why

ROARABLE RATING BRIEF • RQD 20/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

IART — Integra LifeSciences Holdings Corporation: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:31:20Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, IART carries an RQD Score of 20 out of 100, a letter grade of E, and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the Fundamental Cash Engine scores 3/20 (ROIC of -35%; FCF yield of -3.11%), indicating that the business is not currently generating economic returns on invested capital or free cash flow relative to its market value. Whale 13F Flow scores 5/20, reflecting institutional accumulation and options positioning that the source characterizes as weak. Insider Conviction scores 3/20 based on SEC Form 4 and Congressional PTR cluster flow. Macro Regime Fit scores 3/20 with a Beta of 1.0 and sector sensitivity noted. Forensic Balance Sheet scores 6/20, anchored by an Altman Z of 0.64 (a distress-zone reading), a Piotroski F of 4/9, and a Debt/Equity of 0.5. For a prospective investor, the practical implication is that the stock's current price of 12.83 is not supported by the cash-generation, ownership-signal, or balance-sheet metrics in the source data. Any upside case would depend on a reversal in operating performance that the present data does not evidence, and the rating's low scores across four of five pillars point to a high-risk profile for evaluating the stock today.

Business

Per the Profile, Integra LifeSciences Holdings Corporation (IART) is a NASDAQ-listed issuer in the Health Care sector and the Medical/Dental Instruments industry. The source data does not provide a description of specific products, customers, or revenue-generation mechanics beyond the sector and industry classification and the reported financials. Per the Snapshot market data, the company reports a gross margin of 50.9%.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$1635.2M	$-493.4M	$-516.8M	N/A	$-31.1M	$235.0M	N/A
FY 2024	$1610.5M	$28.4M	$-6.9M	N/A	$25.0M	$246.4M	N/A
FY 2023	$1541.6M	$111.5M	$67.7M	N/A	$140.0M	N/A	N/A

Per the SEC financials, revenue rose from $1541.6M in FY 2023 to $1635.2M in FY 2025, while operating income moved from $111.5M to $-493.4M over the same span, and net income moved from $67.7M to $-516.8M. Per the Snapshot market data, the operating margin is -30.2% and the net margin is -31.6%, with ROIC at -35%. Per the Roarable RQD rating, the Altman Z-Score is 0.64 and the Piotroski F-Score is 4/9, with Debt/Equity at 0.5. Cash was $235.0M at FY 2025 versus $246.4M at FY 2024.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is marked NONE, with no butterfly links and no proprietary signals recorded. Sector is Health Care and industry is Medical/Dental Instruments. No upstream or downstream dependencies, sector correlations, or 2nd-order bottlenecks are identified in the source data.

Open Questions

What drove the swing from positive operating income in FY 2024 and FY 2023 to an operating loss of $-493.4M in FY 2025, and is the cause recurring or one-time?
What are the company's debt balances, since the source data lists Debt as N/A for every reported period?
What are the EPS, P/E, and EV/EBITDA figures, which the source data does not provide?
What catalysts or company-specific events are pending, given that no news or catalysts are recorded?
What is the ownership composition (institutional, insider, and 13F holders), which the source data does not list?

IART Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Integra LifeSciences Holdings Corporation (IART) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IART Debate Forum (3) ↓

🟢 CATALYST Yahoo • 3d ago

Integra LifeSciences to Highlight Hands-On Education and Neurosurgery Innovation at CNS 2026 Annual Meeting

Aurora® Surgiscope ® System Aurora® Surgiscope ® System PRINCETON, N.J., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 6d ago

UBS Maintains Neutral on Integra Lifesciences, Lowers Price Target to $14

UBS analyst Patrick Wood maintains Integra Lifesciences (NASDAQ:IART) with a Neutral and lowers the price target from $19 to $14.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 7d ago

3 value stocks we find risky

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable pr

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 7d ago

Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $13

Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and lowers the price target from $15 to $13.

Read Full Source ↗

🔴 RISK WATCH Yahoo • 9d ago

Integra LifeSciences (IART) Stock Sees Fair Value Cut After Analyst Target Reductions

The updated analyst fair value estimate for Integra LifeSciences Holdings has shifted from US$18.38 to US$16.44, which points to a roughly 11% cut in where models now anchor the stock’s longer term potential. This reset

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 11d ago

Citigroup Maintains Neutral on Integra Lifesciences, Lowers Price Target to $14

Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:IART) with a Neutral and lowers the price target from $15 to $14.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 11d ago

BMO Capital Maintains Market Perform on Integra Lifesciences, Lowers Price Target to $14

BMO Capital analyst Vik Chopra maintains Integra Lifesciences (NASDAQ:IART) with a Market Perform and lowers the price target from $15 to $14.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 11d ago

Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Lowers Price Target to $13

Wells Fargo analyst Larry Biegelsen maintains Integra Lifesciences (NASDAQ:IART) with a Equal-Weight and lowers the price target from $15 to $13.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IART Bull vs. Bear Conversation Board — What's Your Call at $12.75?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IART 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $11.29 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is IART (E • RQD 20/100) a Buy at $12.83?

Welcome to the IART (Integra LifeSciences Holdings Corporation) Roar Pit. Current RQD Composite is 20/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $10.65 (-17.0%)

Spot @ $12.83

Pump the brakes on IART — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on IART, but look at what you are paying: current EV/EBITDA multiples with 50.9% gross margins. Unless Integra LifeSciences Holdings Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $14.75 (+15.0%)

Spot @ $12.83

IART cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on IART, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $12.83 (52-wk range $8.70 - $20.49), any beat on forward guidance forces shorts and underweight funds to chase.